Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the <scp>STEP</scp> 7 randomized clinical trial
These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
Authors
- Yiming Mu (ORCID: https://orcid.org/0000-0002-3344-3540)
- Dongmei Liu (ORCID: https://orcid.org/0000-0003-1822-7580)
- Ning Zu (ORCID: https://orcid.org/0000-0003-4208-1630)
- Yibing Lu (ORCID: https://orcid.org/0000-0002-0018-4714)
- Weijun Gu (ORCID: https://orcid.org/0000-0001-8690-645X)
- Guoyue Yuan (ORCID: https://orcid.org/0000-0003-0822-6066)
- Xinhua Ye (ORCID: https://orcid.org/0000-0002-8515-4185)
- Zewei Shen
Institutions
- Jiangsu University (CN)
- Chinese PLA General Hospital (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Changzhou No.2 People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1111/dom.16253
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59